Skip to main content

Tonix Pharmaceuticals

Monday, February 26, 2024
Tonix is a biopharmaceutical company commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s development portfolio is focused on central nervous system disorders. Tonix plans to submit an NDA to the FDA for Tonmya, which has completed two positive Phase 3 studies for the management of fibromyalgia, including a meeting with FDA in the second half of 2024. TNX-102 SL is being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition, and positive topline results from a proof-of-concept study were reported in the third quarter of 2023. Tonix markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg under a transition services agreement with Upsher-Smith Laboratories, LLC from whom the products were acquired in June 2023. Zembrace SymTouch and Tosymra are each indicated for the treatment of acute migraine with or without aura in adults.
Seth Lederman, Chief Executive Officer - TONIX Pharmaceuticals




United States


CEO/Top Company Official

Seth Lederman, M.D. Co-Founder, CEO & Chairman

Lead Product in Development

TNX-102 SL

Development Phase of Primary Product

NDA Preparation/In Review

Double Helix


Supporting Bank Sponsor


Premier Sponsors

Conference Sponsors


Media Partner


Sign up for updates

Stay up-to-date on the BIO CEO and Investor Conference via email.